Novel Angiogenesis Markers as Long‐Term Prognostic Factors in Patients With Renal Cell Cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Genitourinary Cancer

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clgc.2016.07.008PMID 27554585
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma

  2016cited by this paper
• Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.

  2016cited by this paper
• Anti-angiogenic agents in ovarian cancer: past, present, and future.

  2016cited by this paper
• Endothelial cells and cancer cells: metabolic partners in crime?

  2015cited by this paper
• The angiopoietin-Tie2 signaling axis in the vascular leakage of systemic inflammation

  2015cited by this paper
• VEGFR3 and CD31 as prognostic factors in renal cell cancer.

  2015cited by this paper
• Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

  2015cited by this paper
• Biomarkers of renal cell carcinoma.

  2014cited by this paper
• The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma

  2014cited by this paper
• Ki67 is an independent predictor of oncological outcomes in patients with localized clear‐cell renal cell carcinoma

  2014cited by this paper
• Development of renal cell carcinoma (RCC) diagnostics and impact on prognosis

  2014cited by this paper
• Angiopoietin signaling in the vasculature.

  2013cited by this paper
• Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy.

  2013cited by this paper
• Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

  2013cited by this paper
• Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.

  2013cited by this paper
• Angiopoietins in angiogenesis.

  2013cited by this paper
• The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

  2013cited by this paper
• Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.

  2013cited by this paper
• Integrated molecular analysis of clear-cell renal cell carcinoma

  2013cited by this paper
• CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC.

  2012cited by this paper
• The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway.

  2012cited by this paper
• AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

  2012cited by this paper
• VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.

  2009cited by this paper
• Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

  2009cited by this paper
• Renal cell carcinoma

  2009cited by this paper
• Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.

  2009cited by this paper
• TNM Classification of Malignant Tumours, 7th Edition

  2009cited by this paper
• Angiopoietins in malignancy.

  2007cited by this paper
• Renal cell carcinoma

  2007cited by this paper
• Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis.

  2004cited by this paper
• Increased expression of caveolin‐1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma

  2004cited by this paper
• Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients

  2004cited by this paper
• Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma.

  2003cited by this paper
• Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel‐Lindau gene and hypoxia

  2002cited by this paper
• Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

  1999cited by this paper
• Prognostic significance of morphologic parameters in renal cell carcinoma

  1982cited by this paper

• Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis

  2023cites this paper
• The possible dual role of Ang-2 in the prognosis of pancreatic cancer

  2023cites this paper
• Anti-angiogenic Targets: Angiopoietin and Angiopoietin Receptors

  2019cites this paper
• Anti-angiogenic Targets: Angiopoietin and Angiopoietin-Receptors

  2018cites this paper
• ENHANCER OF ZESTE HOMOLOG 2 AND VASCULAR ENDOTHELIAL GROWTH FACTOR IMMUNOHISTOCHEMICAL EXPRESSION ARE ASSOCIATED WITH ADVERSE CLINICAL OUTCOME IN NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA.

  2017cites this paper
• A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.

  2017cites this paper
• Signalling and expression of the Ang-Tie pathway in tumor vasculature

  2016cites this paper